Events:
On January 14, 2016, the company announced its 2015 results KuaiBao. Revenue for the reporting period was 2.299 billion, an increase of 42.63% over the same period last year; operating profit was 70.565 million, down 2.26% from the same period last year; total profit was 737.17 billion yuan, up 2.89% from the same period last year; and net profit was 64.567 million, an increase of 5.75% compared with the same period last year.
Investment viewpoint:
Subject to the increase in costs, the income growth of the main business exceeded expectations, but the performance growth was weak.
The company expanded its marketing channel, with revenue of 2.299 billion in 15 years, an increase of 42.63% over the same period last year, and higher-than-expected revenue growth, but operating profit increased by 70.56 million, down 2.26% from the same period last year. Mainly due to the following three reasons: 1) increased R & D investment, R & D expenditure of 28.27 million in 2015, the employment of high-tech personnel to enhance the strength of the R & D team, including FDA certification and polypeptide technology R & D personnel, the cost increased 2) the financial expenses have increased significantly, and the company's extensive mergers and acquisitions and Ningbo tumor base have invested a lot of money, which makes the company's asset-liability ratio exceed 30%, which is significantly higher than 5.3% in the same period in 2014. the company's financial expense rate increased from-2.87% to 6.7%, and the annual financial expenses exceeded 10 million yuan, compared with-4.63 million yuan in 2014. 3) the incentive cost of new employees in 2015.
Australia-Asia CMO business expansion to promote Shuangcheng strategic transformation
The company has acquired 46% stake in Hangzhou Australia and Asia, cut into the preparation CMO business, and the remaining equity is expected to be acquired through a fixed increase. Australia and Asia are mainly focused on the contract manufacturing and production of injections, and invested 50 million to establish a freeze-drying university, the established MES system can real-time monitor the whole production process online to ensure quality, the boss is a craftsman, has more than 20 years of research experience in freeze-drying process, Australia and Asia is the standard setter of domestic freeze-drying process. Australia and Asia have a long-term strategic cooperative relationship with Fudan Fuhua and Green Leaf Pharmaceutical. Although the performance of Australia and Asia was lower than expected in 2015 due to industry changes affecting customer sales, it is expected to expand and extend its new business in the future: 1) to help customers improve the freeze-dried injection process, and seek cooperation with CRO enterprises to extend upstream and export technology. 2) expand international CMO orders, accelerate internationalization, and do international contract manufacturing preparations of European and American standards in CMO enterprises. 3) is beginning to seek cooperation in the freeze-dried production of cosmetics. 4) Australia and Asia are expected to benefit from the landing of the listing licensor system, resulting in an increase in orders.
Establishment of pharmaceutical industry M & A fund to help companies accelerate the landing of epitaxial mergers and acquisitions
Shihezi Shuangcheng, a related party of the company, set up a merger and acquisition fund of about 2 billion with Beijing Qilong Pharmaceutical Company, aiming at upgrading Shuangcheng Pharmaceutical's health strategy, supporting and helping the company to realize related mergers and acquisitions. With the support of a professional investment team and the docking of its resources in the field of medicine and biology, it is expected to accelerate the pace of the company's extension.
Profit forecast and valuation: 46% equity in Australia and Asia is included in equity investment income, and the company's 15-16 year EPS is expected to be 0.16,0.22,0.29 yuan respectively, corresponding to 70.3,48,36 times PE. The new corporate thymus method continues to grow steadily, has a clear international development route, is at a turning point in transformation and development, and maintains a "highly recommended" rating.
Risk hint: single product risk, R & D and epitaxial mergers and acquisitions do not meet expectations.